1
|
Hebb ALO, Moore CS, Bhan V, Campbell T, Fisk JD, Robertson HA, Thorne M, Lacasse E, Holcik M, Gillard J, Crocker SJ, Robertson GS. Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. Mult Scler 2008; 14:577-94. [DOI: 10.1177/1352458507087468] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
A failure of autoreactive T cells to undergo apoptosis may contribute to the pathogenesis of multiple sclerosis (MS). The role of the inhibitor of apoptosis (IAP) family of anti-apoptotic proteins such as X-linked IAP (XIAP), human inhibitor of apoptosis-1 (HIAP-1), human inhibitor of apoptosis-2 (HIAP-2), neuronal apoptosis inhibitory protein (NAIP) and Survivin in relapsing–remitting, secondary-progressive, primary-progressive or benign forms of MS is unclear. We report here that expression of the IAP family of genes in peripheral blood samples and brain tissues from MS cases support a role for differential regulation of these potent anti-apoptotic proteins in the pathology of MS. XIAP mRNA and protein levels were elevated in peripheral blood mononuclear cells from patients with active disease relative to normal subjects. In patients with active MS, HIAP-1 and HIAP-2 mRNA levels were elevated in resting T cells while NAIP mRNA was increased in whole blood. In post-mortem MS brain tissue, XIAP and HIAP-1 in myelin lesions were co-localized with microglia and T cells, respectively. Only in primary-progressive patients was Survivin expression elevated suggestive of a distinct pathological basis for this subtype of MS. Taken together, these results suggest that patterns of inhibitor of apoptosis expression in immune cells may have value in distinguishing between MS subtypes and offer insight into the mechanisms responsible for their distinct clinical courses.
Collapse
Affiliation(s)
- ALO Hebb
- Department of Pharmacology, Dalhousie University, Halifax, NS, B3H 1X5, Canada
| | - CS Moore
- Department of Pharmacology, Dalhousie University, Halifax, NS, B3H 1X5, Canada
| | - V Bhan
- Department of Medicine (Neurology), Dalhousie University, Halifax, NS, B3H 1V7, Canada
| | - T Campbell
- Department of Medicine (Neurology), Dalhousie University, Halifax, NS, B3H 1V7, Canada
| | - JD Fisk
- Department of Psychiatry, Dalhousie University, Halifax, NS, B3H 2E2, Canada; Department of Psychology, QEII Health Sciences Centre, Halifax, NS, B3H 2E2, Canada
| | - HA Robertson
- Department of Pharmacology, Dalhousie University, Halifax, NS, B3H 1X5, Canada
| | - M Thorne
- Department of Pharmacology, Dalhousie University, Halifax, NS, B3H 1X5, Canada
| | - E Lacasse
- Aegera Therapeutics Inc., Nun’s Island (Montreal), PQ, H3E 1A8, Canada
| | - M Holcik
- Apoptosis Research Centre, Children's Hospital of Eastern Ontario, Ottawa, Ontario, KIH 8L1, Canada
| | - J Gillard
- Aegera Therapeutics Inc., Nun’s Island (Montreal), PQ, H3E 1A8, Canada
| | - SJ Crocker
- Molecular and Integrative Neuroscience Department, the Scripps Research Institute, La Jolla, CA, 92037, USA
| | - GS Robertson
- Department of Pharmacology, Dalhousie University, Halifax, NS, B3H 1X5, Canada; Department of Psychiatry, Dalhousie University, Halifax, NS, B3H 2E2, Canada
| |
Collapse
|